+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy

Clinical Microbiology and Infection 13(6): 579-585

Isolates of Pseudomonas aeruginosa (n = 208) were collected from an 810-bed hospital in Connecticut, USA. A model employing the pharmacokinetic properties of meropenem, susceptibility results and Monte Carlo simulation was used to analyse four different dosing regimens of meropenem at pharmacodynamic endpoints. Cumulative fraction of response (CFR) was assessed at bacteriostatic and bactericidal endpoints for the entire population of isolates, as well as for isolates from principal anatomical sites. CFR was also evaluated at endpoints shown to suppress emergence of resistance in 'susceptible'P. aeruginosa with either monotherapy or combination therapy. The bacteriostatic/bactericidal CFR of meropenem 1 g every 8 h (q8h), 2 g q8h, 1 g q8h infused over 3 h (3-h INF), and 2 g q8h 3-h INF were 76%/73%, 80%/76%, 77%/75% and 79%/78%, respectively. At the monotherapeutic suppressive endpoint, CFRs against susceptible isolates were 21%, 35%, 32% and 50%, respectively. When combination therapy with an aminoglycoside was simulated, the CFRs for the same regimens were 50%, 64%, 65% and 79%, respectively. Bactericidal CFRs for all regimens against wound isolates were significantly higher (p <0.03 for each regimen) than CFRs for the entire population. Meropenem 2 g q8h with a 3-h infusion in combination with an aminoglycoside provides the greatest likelihood of P. aeruginosa coverage, and may help to prevent development of resistance, although local MIC data are essential to inform therapeutic decisions.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048181064

Download citation: RISBibTeXText

PMID: 17331121

DOI: 10.1111/j.1469-0691.2007.01693.x

Related references

Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase. Antimicrobial Agents and ChemoTherapy 63(6), 2019

In vivo pharmacodynamic characterization of meropenem and its impact on the selection of resistance among Pseudomonas aeruginosa. Pharmacotherapy 23(10): 1344, 2003

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and ChemoTherapy 62(4), 2018

The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrobial Agents and ChemoTherapy 54(6): 2646-2654, 2010

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant Pseudomonas aeruginosa Strains. Chemotherapy 49(6): 294-297, 2003

In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. ChemoTherapy 49(6): 294-297, 2003

Successful combination therapy by meropenem and colistin for multi-drug-resistant Pseudomonas aeruginosa infection after allogeneic bone marrow transplantation. Japanese Journal of Clinical Hematology 52(3): 118-123, 2011

Pharmacodynamic evaluation of meropenem and imipenem against Pseudomonas aeruginosa and Enterobacter species using Monte Carlo analysis. Pharmacotherapy 22(10): 1351-1352, 2002

Mathematical modelling response of Pseudomonas aeruginosa to meropenem. Journal of Antimicrobial ChemoTherapy 60(6): 1302-1309, 2007

Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139(5): 1172-1185, 2011

Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrobial Agents and ChemoTherapy 53(6): 2266-2273, 2009

Meropenem resistance in Pseudomonas aeruginosa. ChemoTherapy 42(1): 47-56, 1996

In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 25(2): 181-182, 2005

Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrobial Agents and ChemoTherapy 57(6): 2788-2792, 2013

Relationship between Meropenem Use and Resistance Rate of Pseudomonas Aeruginosa. Journal Of The Japanese Association Of Rural Medicine 66(4): 481-486, 2017